Edition:
United States

Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

50.56USD
19 Oct 2017
Change (% chg)

$-0.53 (-1.04%)
Prev Close
$51.09
Open
$51.20
Day's High
$51.37
Day's Low
$50.23
Volume
600,587
Avg. Vol
733,582
52-wk High
$63.40
52-wk Low
$42.64

Chart for

About

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central... (more)

Overall

Beta: 2.17
Market Cap(Mil.): $7,850.33
Shares Outstanding(Mil.): 153.66
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 90.61 17.08
EPS (TTM): -- -- --
ROI: -- 2.45 11.26
ROE: -- 3.37 15.09

BRIEF-Alkermes qtrly gaap loss per share $0.28

* Qtrly revenues increased 12% year-over-year to $218.8 million

Jul 27 2017

BRIEF-Alkermes announces positive preliminary topline results

* Alkermes announces positive preliminary topline results from phase 3 antipsychotic efficacy study of ALKS 3831 for treatment of schizophrenia

Jun 29 2017

BRIEF-Alkermes announces initiation of study 217 for ALKS 5461

* Alkermes announces initiation of study 217 for ALKS 5461 for treatment of major depressive disorder

Jun 12 2017

BRIEF-Alkermes initiates phase 3 study of ALKS 3831 in young adult patients

* Alkermes announces initiation of phase 3 study of alks 3831 in young adult patients

Jun 08 2017

Competitors

Earnings vs. Estimates